Retrospective analysis of treatment outcome and side effects of testicular cancer patients that had been diagnosed at the University Magdeburg from 1960 until 2012.
Creating an ACCESS Windows form based Data Registry for testicular cancer patients. Relevant data for testicular cancer patients based on EAU-guidelines 2013 and EORTC/RTOG, Lent-SOMA, CTC. All testicular cancer patients who had been histopathologically diagnosed al the Institute of Pathology at the University Magdeburg. About 2000 patients from 1960 until 2012. Postgraduate students collecting data requesting hospital documents, cancer registry of Sachsen-Anhalt, family practitioners and urologists as well as patients. Statistically Analysis with ACCESS and IBM SPSS statistics.
Study Type
OBSERVATIONAL
Enrollment
2,000
Urology University Magdeburg
Magdeburg, Saxony-Anhalt, Germany
Overall survival (OS)
Overall survival (OS).
Time frame: Up to 52 years.
Disease-specific survival.
Disease-specific survival of testicular cancer.
Time frame: Up to 52 years.
Chronic side effects of testicular-cancer-specific radiation therapies.
All Therapy Associated side effects of radiation therapy using EORTC (European Organisation for Research and Treatment of Cancer) /RTOG- (Radiation Therapy Oncology Group) - RTOG/EORTC Late Radiation Morbidity Scoring Schema), LENT-SOMA-(Late Effects of Normal Tissues)-, CTCAE-(Common Terminology Criteria for Adverse Events V4)-Scores. See
Time frame: Up to 52 years.
Chronic side effects of testicular-cancer-specific chemotherapies.
All Therapy Associated side effects of chemotherapy using CTCAE-(Common Terminology Criteria for Adverse Events V4)-Score.
Time frame: Up to 52 years.
Chronic side effects of testicular-cancer-specific surgical therapies.
All Therapy Associated side effects of surgical therapy using CTCAE-(Common Terminology Criteria for Adverse Events V4)-Score.
Time frame: Up to 52 years.
Secondary Malignoma
Assessment of Development of Secondary malignoma after diagnosis of testicular cancer; Secondary malignoma other than testicular cancer and metachronous Primary testicular cancer
Time frame: Up to 52 years.
Progressive-free survival (PFS).
Progressive-free survival (PFS).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 52 years.
Relapse-free survival (RLS).
Relapse-free survival (RLS).
Time frame: Up to 52 years.
Quality of Life (QoL).
Assessment of the current QoL using ECOG and EORTC-QLQ-C30-V3D.
Time frame: Current situation.
Cause of death.
Cause of death.
Time frame: Up to 52 years.